



Subsidiary Form PTO-1449

Atty. Docket No.: 26473/04195

Serial No.: 09/931,28

**APPLICANT'S INFORMATION
DISCLOSURE STATEMENT**

Applicant: Hazen, et al.

Filing Date: August 16, 2001

Group: 1644

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Dat
	AA						
	AB						
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translatio
	AE	1,008,594	October 27, 1965	GB			
	AF						
	AG						
	AH						
	AI						


OTHER PRIOR ART

	AJ	Supplementary European Search Report dated February 13, 2002.
	AK	"3-Bromo and 3,5-Dibromotyrosine: potential markers for eosinophil-dependent injury in vivo" by Hazen, et al. <u>Free Radical Biology and Medicine</u> , Vol. 25, No. Supp. 1, November 1998 (1998-11), p. 209.
	AL	"3-Bromotyrosine and 3,5-Dibromotyrosine are major products of protein oxidation by eosinophil peroxidase potential markers for eosinophil-dependent tissue injury in vivo" by Wu, et al., <u>Biochemistry</u> , No. 39, 1999, pp. 3538-3548.
	AM	"Synthesis and specific tritium labelling of the behaviourally active octapeptide des-9-glycinamide-lysine-vasopressin in two different amino acid residues" by Keri, et al., <u>Journal of Labelled Compounds and Radiopharmaceuticals</u> , Vol. 15, 1978, pp. 163-168.
	AN	
	AO	
	AP	
	AQ	
	AR	

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.



Subst. Form PTO-1449

Patent No.: 26473/04195

Serial No.: 09/931,287

APPLICANT'S INFORMATION
DISCLOSURE STATEMENT

Applicant: Hazen, et al.

Filing Date: August 16, 2001

Group: 1644

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Initial*	Document No.	Date	Name	Class	Subcl.	Filing Date
AA	5,710,2485 ✓	January 20, 1998	Grose			July 29, 1996
AB	6,306,576 ✓	October 23, 2001	Hazen			Feb. 19, 1999
AC						
AD						

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Subcl.	Translation?
AE	98/10295	12 March 1998	WO			
AF						
AG						
AH						
AI						

OTHER PRIOR ART

AJ	"Protein epitopes: functional vs. structural definitions" by S.J. Smith-Gill, 55 th Forum in Immunology, pp. 67-70. ✓
AK	"The Merck Manual of Diagnosis and Therapy", Sixteenth Edition, 1992, pp. 1229-1233. ✓
AL	Abstract 209, "3-Bromo- and 3,5-Dibromo-Tyrosine: Potential Markers for Eosinophil-Dependent Injury <i>In Vivo</i> " by Hazen, et al., 5 th Annual Meeting of the Oxygen Society, November 19-23, 1998, Washington, D.C. ✓
AM	"Eosinophilia" by Rothenberg, <u>The New England Journal of Medicine</u> , Vol. 338, No. 22, May 28, 1998, pp. 1592-1600. ✓
AN	"3-Bromotyrosine and 3,5-Dibromotyrosine Are Major Products of Protein Oxidation by Eosinophil Peroxidase: Potential Markers for Eosinophil-Dependent Tissue Injury in Vivo" by Wu, et al., <u>Biochemistry</u> , Vol. 38, No. 12, 1999, pp. 3538-3548. ✓
AO	"Role of eosinophil peroxidase in the origins of protein oxidation in asthma" by Mitra, et al., <u>Redox Report</u> , Vol. 5, No. 4, 2000, pp. 215-224. ✓
AP	"Eosinophils generate brominating oxidants in allergen-induced asthma" by Wu, et al., <u>The Journal of Clinical Investigation</u> , Vol. 105, No. 10, May 2000, pp. 1455-1463. ✓
AQ	
AR	

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.